Nanopublication

ID

http://purl.org/np/RA_oI-ncugFmT2Sae4sIvA5x79B79QFxBP8K68MO35Gbs
Formats

Content

@prefix this: <http://purl.org/np/RA_oI-ncugFmT2Sae4sIvA5x79B79QFxBP8K68MO35Gbs> .
@prefix sub: <http://purl.org/np/RA_oI-ncugFmT2Sae4sIvA5x79B79QFxBP8K68MO35Gbs#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix pav: <http://purl.org/pav/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix umls: <http://identifiers.org/umls/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix unii: <http://identifiers.org/unii/> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo .
}

sub:assertion {
  umls:C1299487 a biolink:OrganismTaxon;
    rdfs:label "patients";
    biolink:category biolink:OrganismTaxon .
  
  unii:0K47UL67F2 a biolink:ChemicalEntity;
    rdfs:label "Carvedilol";
    biolink:category biolink:ChemicalEntity .
  
  <http://purl.obolibrary.org/obo/CHEBI_50264> a biolink:ChemicalEntity;
    rdfs:label "thiazide";
    biolink:category biolink:ChemicalEntity .
  
  <http://purl.obolibrary.org/obo/MONDO_0005068> a biolink:DiseaseOrPhenotypicFeature;
    rdfs:label "myocardial infarction";
    biolink:category biolink:DiseaseOrPhenotypicFeature .
  
  sub:_1 a biolink:Association;
    rdf:object <http://purl.obolibrary.org/obo/CHEBI_50264>;
    rdf:predicate biolink:treated_by;
    rdf:subject <http://purl.obolibrary.org/obo/MONDO_0005068>;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> .
  
  sub:_2 a biolink:Association;
    rdf:object <http://purl.obolibrary.org/obo/CHEBI_50264>;
    rdf:predicate biolink:treats;
    rdf:subject unii:0K47UL67F2;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> .
  
  sub:_3 a biolink:Association;
    rdf:predicate biolink:treats;
    rdf:subject unii:0K47UL67F2;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> .
  
  sub:_4 a biolink:Association;
    rdf:predicate biolink:treats;
    rdf:subject unii:0K47UL67F2;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> .
  
  sub:_5 a biolink:Association;
    rdf:object <http://purl.obolibrary.org/obo/CHEBI_50264>;
    rdf:predicate biolink:treated_by;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> .
  
  sub:_6 a biolink:Association;
    rdf:object <http://purl.obolibrary.org/obo/MONDO_0005068>;
    rdf:predicate biolink:treats;
    rdf:subject unii:0K47UL67F2;
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:Association;
    biolink:publications <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=278a60c4-2353-4657-b486-f392b93181b7> .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2022-10-11T07:14:02.124516"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-3668-2627;
    prov:wasQuotedFrom " Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40%. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. It is indicated for the management of essential. essential. heart failure." .
  
  biolink: pav:version "2.3.0" .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB";
    npx:hasSignature "U/r65UOfFROfafNoL599E6jgtio6BnZAIOQ1yWdFWz31jXT3rO1XdUkfRnFBq0DJBvvLCK6Kgx3dPyzLSxzt4c9/yLUpeWGwA2P6nHElBdOI3E2TPwHNUPGoPM7kjPyL2Jvb6GbpBIpfxJ1oDg7V3VISyL+TYzo8C4zyPsuOawgFdwpv5GRmVcxQikIyseagaWl8jyXG8m67wo16NoNUUoT4UACC70paz+bzcSlgcVxCe4y5TL+nXAzUCM9T8KvBMe714vlQ8/duaRBOhT2Qy0N6qB5gdFeDOWCqvH3VFUtSqqaEQSrrIFvOCO3Ydiuu8DRsmg69hVheB/qGTG5vUA==";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2022-10-11T07:14:02.124516"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-3668-2627 .
}